{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T08:01:59Z","timestamp":1742803319862},"reference-count":50,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2018.4438","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T09:49:03Z","timestamp":1528796943000},"source":"Crossref","is-referenced-by-count":6,"title":["Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2"],"prefix":"10.3892","author":[{"given":"Yongsheng","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxuan","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiucai","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaikang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingcong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houcai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"key20200713184958_b1-ijo-53-02-0823","first-page":"109","article-title":"Recommendations for clinical trial development in mantle cell lymphoma","volume":"109","author":"Spurgeon","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"key20200713184958_b2-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"key20200713184958_b3-ijo-53-02-0823","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","article-title":"PRAD-1\/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma","volume":"84","author":"Bosch","year":"1994","journal-title":"Blood"},{"key":"key20200713184958_b4-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20200713184958_b5-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1200\/JCO.2012.47.2829","article-title":"Primary cutaneous mantle-cell lymphoma: A case report and literature review","volume":"33","author":"Hamad","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20200713184958_b6-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: Evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"key":"key20200713184958_b7-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/bcp.12888","article-title":"Targeting mTOR for the treatment of B cell malignancies","volume":"82","author":"Lee","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"key20200713184958_b8-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ctrv.2008.09.006","article-title":"The role of mTOR in the management of solid tumors: An overview","volume":"35","author":"Strimpakos","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"key20200713184958_b9-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2174\/156800908786733513","article-title":"mTOR pathway and mTOR inhibitors as agents for cancer therapy","volume":"8","author":"Baldo","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"key20200713184958_b10-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat Genet"},{"key":"key20200713184958_b11-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2007.05.058","article-title":"IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"key20200713184958_b12-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bjh.12945","article-title":"Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies","volume":"166","author":"Eyre","year":"2014","journal-title":"Br J Haematol"},{"key":"key20200713184958_b13-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","article-title":"Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma","volume":"169","author":"Peponi","year":"2006","journal-title":"Am J Pathol"},{"key":"key20200713184958_b14-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"key20200713184958_b15-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713184958_b16-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"key20200713184958_b17-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1182\/blood-2011-04-346601","article-title":"Dual mTORC1\/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"key20200713184958_b18-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20200713184958_b19-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"key20200713184958_b20-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2015.05.011","article-title":"Treatment of obesity with celastrol","volume":"161","author":"Liu","year":"2015","journal-title":"Cell"},{"key":"key20200713184958_b21-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2010.10.025","article-title":"Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer","volume":"303","author":"Kannaiyan","year":"2011","journal-title":"Cancer Lett"},{"key":"key20200713184958_b22-ijo-53-02-0823","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2006-10-050807","article-title":"Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation","volume":"109","author":"Sethi","year":"2007","journal-title":"Blood"},{"key":"key20200713184958_b23-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2010.09.006","article-title":"Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor \u03b1","volume":"300","author":"Jang","year":"2011","journal-title":"Cancer Lett"},{"key":"key20200713184958_b24-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.yexcr.2014.08.014","article-title":"Celastrol induces unfolded protein response-dependent cell death in head and neck cancer","volume":"330","author":"Fribley","year":"2015","journal-title":"Exp Cell Res"},{"key":"key20200713184958_b25-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"19634","DOI":"10.1021\/ja208359a","article-title":"Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol","volume":"133","author":"Klai\u0107","year":"2011","journal-title":"J Am Chem Soc"},{"key":"key20200713184958_b26-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/abbs\/gmx021","article-title":"Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1\/2 and IL-6\/STAT3 pathways in vitro and in vivo","volume":"49","author":"Hu","year":"2017","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"key20200713184958_b27-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-14-3763","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method - letter","volume":"75","author":"Ashton","year":"2015","journal-title":"Cancer Res"},{"key":"key20200713184958_b28-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3324\/haematol.2017.177162","article-title":"Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment","volume":"103","author":"Rudelius","year":"2018","journal-title":"Haematologica"},{"key":"key20200713184958_b29-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1093\/nar\/gkt125","article-title":"Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells","volume":"41","author":"Zhou","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"key20200713184958_b30-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: Positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev"},{"key":"key20200713184958_b31-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"150845","DOI":"10.1155\/2014\/150845","article-title":"Apoptosis and molecular targeting therapy in cancer","volume":"2014","author":"Hassan","year":"2014","journal-title":"BioMed Res Int"},{"key":"key20200713184958_b32-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrm2312","article-title":"Apoptosis: Controlled demolition at the cellular level","volume":"9","author":"Taylor","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200713184958_b33-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","article-title":"Targeting BCL-2 in B-cell lymphomas","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"key":"key20200713184958_b34-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"key20200713184958_b35-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"18934","DOI":"10.1074\/jbc.M101103200","article-title":"Akt stimulates the transactivation potential of the RelA\/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38","volume":"276","author":"Madrid","year":"2001","journal-title":"J Biol Chem"},{"key":"key20200713184958_b36-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.2174\/18715206113139990078","article-title":"Targeted regulation of PI3K\/Akt\/mTOR\/NF-\u03baB signaling by indole compounds and their derivatives: Mechanistic details and biological implications for cancer therapy","volume":"13","author":"Ahmad","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"key20200713184958_b37-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0124","article-title":"Oncogenic EGFR signaling activates an mTORC2-NF-\u03baB pathway that promotes chemotherapy resistance","volume":"1","author":"Tanaka","year":"2011","journal-title":"Cancer Discov"},{"key":"key20200713184958_b38-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.immuni.2010.06.002","article-title":"Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways","volume":"32","author":"Lee","year":"2010","journal-title":"Immunity"},{"key":"key20200713184958_b39-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0165-6147(03)00026-9","article-title":"Cell-cycle dysregulation and anticancer therapy","volume":"24","author":"Stewart","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"key20200713184958_b40-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science"},{"key":"key20200713184958_b41-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrm2153","article-title":"The apoptosome: Signalling platform of cell death","volume":"8","author":"Riedl","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200713184958_b42-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: Effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist Updat"},{"key":"key20200713184958_b43-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: Insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20200713184958_b44-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes Dev"},{"key":"key20200713184958_b45-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"key":"key20200713184958_b46-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1159\/000453163","article-title":"The mTORC2\/Akt\/NF\u03baB pathway-mediated activation of TRPC6 participates in adriamycin-induced podocyte apoptosis","volume":"40","author":"Zhang","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"key20200713184958_b47-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1084\/jem.20111470","article-title":"Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia","volume":"209","author":"Lee","year":"2012","journal-title":"J Exp Med"},{"key":"key20200713184958_b48-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1038\/sj.onc.1209942","article-title":"Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression","volume":"25","author":"Bass\u00e8res","year":"2006","journal-title":"Oncogene"},{"key":"key20200713184958_b49-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"key20200713184958_b50-ijo-53-02-0823","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood-2015-02-629485","article-title":"4EBP1\/c-MYC\/PUMA and NF-\u03baB\/EGR1\/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells","volume":"127","author":"Yun","year":"2016","journal-title":"Blood"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T18:58:39Z","timestamp":1594666719000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2018.4438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":50,"URL":"https:\/\/doi.org\/10.3892\/ijo.2018.4438","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,12]]}}}